KROS:NASDAQKeros Therapeutics, Inc. analysis

Keros Therapeutics trades at $10.65, well below its 20‑day (10.61), 50‑day (11.09) and 200‑day (14.97) simple moving averages, confirming a bearish price trend. The RSI sits at 49.8, indicating no clear momentum, while the MACD line is slightly above its signal, giving a marginal bullish hint but not enough to offset the overall downtrend. The stock sits above a near‑term support of $9.69 and below resistance at $11.63, with 30‑day volatility soaring above 54% and a beta above 1, suggesting heightened price swings.
Fundamentally, KROS reports a massive revenue decline (‑99.8%) and deep negative margins (gross ‑184%, operating ‑70%). Despite a strong cash position of $281.5 M, the company burns cash (operating cash flow ‑$57.2 M) and carries a high debt‑to‑equity ratio of 5.7. Valuation metrics show the price is below book (P/B 0.74) and the market expects a potential upside of over 100% per analyst targets, yet earnings missed expectations with a 31% negative surprise. The biotech sector’s regulatory risk and the company’s clinical‑stage pipeline add further uncertainty.